C
Carsten Bokemeyer
Researcher at University of Hamburg
Publications - 722
Citations - 28882
Carsten Bokemeyer is an academic researcher from University of Hamburg. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 74, co-authored 633 publications receiving 24857 citations. Previous affiliations of Carsten Bokemeyer include Eppendorf (Germany) & University of Zurich.
Papers
More filters
Journal ArticleDOI
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Jan B. Vermorken,Ricard Mesia,Fernando Rivera,Eva Remenar,Andrzej Kawecki,Sylvie Rottey,Jozsef Erfan,Dmytro Zabolotnyy,Heinz Roland Kienzer,Didier Cupissol,Frederic Peyrade,Marco Benasso,Ihor Vynnychenko,Dominique De Raucourt,Carsten Bokemeyer,Armin Schueler,Nadia Amellal,Ricardo Hitt +17 more
TL;DR: Adding cetuximab to platinum-based chemotherapy with fluorouracil (platinum-fluorouracils) significantly prolonged the median overall survival and improved overall survival when given as first-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck.
Journal ArticleDOI
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study.
Dominic Wichmann,Jan-Peter Sperhake,Marc Lütgehetmann,Stefan Steurer,Carolin Edler,Axel Heinemann,Fabian Heinrich,Herbert Mushumba,Inga Kniep,Ann Sophie Schröder,Christoph Burdelski,Geraldine de Heer,Axel Nierhaus,Daniel Frings,Susanne Pfefferle,Heinrich Becker,Hanns Bredereke-Wiedling,Andreas de Weerth,Hans-Richard Paschen,Sara Sheikhzadeh-Eggers,Axel Stang,Stefan Schmiedel,Carsten Bokemeyer,Marylyn M. Addo,Martin Aepfelbacher,Klaus Püschel,Stefan Kluge +26 more
TL;DR: In this paper, the causes of COVID-19-related deaths were investigated in a single academic medical center in the German federal state of Hamburg for patients dying with a polymerase chain reaction-confirmed diagnosis of CoV-19 patients.
Journal ArticleDOI
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Carsten Bokemeyer,Igor Bondarenko,A. Makhson,Joerg T. Hartmann,Jorge Aparicio,Filippo de Braud,Serban Donea,Heinz Ludwig,Gunter Schuch,Christopher Stroh,Anja H. Loos,A. Zubel,Piotr Koralewski +12 more
TL;DR: KRAS mutational status was shown to be a highly predictive selection criterion in relation to the treatment decision regarding the addition of cetuximab to FOLFOX-4 for previously untreated patients with metastatic colorectal cancer.
Journal ArticleDOI
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
Carsten Bokemeyer,Igor Bondarenko,Joerg T. Hartmann,F. de Braud,G. Schuch,A. Zubel,Ilhan Celik,Michael Schlichting,P. Koralewski +8 more
TL;DR: These results confirm the efficacy of cetuximab plus FOLFOX-4 in the first-line treatment of patients with KRAS wild-type mCRC and confirm KRAS mutation status as an effective predictive biomarker.
Journal ArticleDOI
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I
Susanne Krege,Jörg Beyer,Rainer Souchon,Peter Albers,Walter Albrecht,Ferran Algaba,Michael Bamberg,István Bodrogi,Carsten Bokemeyer,Eva Cavallin-Ståhl,Johannes Classen,C Clemm,Gabriella Cohn-Cedermark,Stéphane Culine,Gedske Daugaard,Pieter H.M. De Mulder,Maria De Santis,Maike de Wit,Ronald de Wit,H. G. Derigs,Klaus Peter Dieckmann,Annette Dieing,Jean Pierre Droz,Martin Fenner,Karim Fizazi,Aude Flechon,Sophie D. Fosså,Xavier Garcia del Muro,Thomas Gauler,Lajos Géczi,Arthur Gerl,Jose Ramon Germa-Lluch,Silke Gillessen,Jörg T. Hartmann,Michael Hartmann,Axel Heidenreich,Wolfgang Hoeltl,Alan Horwich,Robert Huddart,Michael Jewett,Johnathan Joffe,William G. Jones,László Kisbenedek,Olbjørn Klepp,S. Kliesch,Kai Uwe Koehrmann,Christian K. Kollmannsberger,Markus A. Kuczyk,Pilar Laguna,Oscar Leiva Galvis,Volker Loy,Malcolm David Mason,Graham M. Mead,Rolf Mueller,Craig R. Nichols,Nicola Nicolai,Tim Oliver,D. Ondruš,Gosse O N Oosterhof,Luis Paz Ares,Giorgio Pizzocaro,Jörg Pont,Tobias Pottek,Thomas Powles,Oliver Rick,Giovanni Rosti,Roberto Salvioni,Jutta Scheiderbauer,Hans U. Schmelz,Heinz Schmidberger,Hans-Joachim Schmoll,Mark Schrader,Felix Sedlmayer,Niels E. Skakkebæk,Aslam Sohaib,Sergei Tjulandin,Padraig Warde,Stefan Weinknecht,Lothar Weissbach,Christian Wittekind,Eva Winter,Lori Wood,Hans von der Maase +82 more
TL;DR: F refinements in the treatment of early- and advanced-stage testicular cancer have emerged from clinical trials, and expert clinical skills will continue to be one of the major determinants for the prognosis of patients with germ cell cancer.